Completed PHASE1 INTERVENTIONAL 4-arm NCT00985959

A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)

A Phase I/II Clinical Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)

Sponsor: Janssen Pharmaceutical K.K.

Conditions Multiple Myeloma

Interventions JNJ-26866138 0.7 mg/m2 JNJ-26866138 1.0 mg/m2 JNJ-26866138 1.3 mg/m2 Melphalan Prednisolone

Updated 6 times since 2017 Last updated: Oct 31, 2013 Started: Jul 31, 2008 Primary completion: Jun 30, 2010 Completion: Jun 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Multiple Myeloma and is currently completed. Janssen Pharmaceutical K.K. leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jul 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Pharmaceutical K.K.

Data source: Janssen Pharmaceutical K.K.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Fukuoka, Japan , Hiroshima, Japan , Hitachi, Japan , Isehara, Japan , Kamogawa, Japan , Kanazawa, Japan , Kawagoe, Japan , Kobe, Japan , Kumamoto, Japan , Kurashiki, Japan and 18 more locations